Literature DB >> 6586489

Transfer of terbutaline across the human placenta in late pregnancy.

B Bergman, H Bokström, O Borgå, L Enk, T Hedner, B Wängberg.   

Abstract

Placental transfer of terbutaline was studied in 22 women in late pregnancy who were delivered by elective Caesarian section. A single i.v. dose of terbutaline (0.25 or 0.5 mg) was given at various times (13-295 min) before delivery. Immediately after delivery, one blood sample was drawn from the placental side of the umbilical vein and one from the mother's antecubital vein. By use of gas chromatography plus mass spectrometry terbutaline was assayed in maternal plasma and in plasma and whole blood from the umbilical vein. Plasma concentrations in the mothers (Cmv) were initially 7 micrograms/L, while the highest umbilical venous level ( Cuv ) recorded was 3.5 micrograms/L. The ratio Cuv /Cmv increased continuously during the time interval studied and approached unity after 2-3 h. The blood:plasma concentration ratio in venous umbilical blood was initially low. It reached unity after about 60 min, but increased steadily to about 1.5 during the time of study. Thus there was a continuous uptake of terbutaline from plasma into the erythrocytes. The slow in vivo equilibration of terbutaline between plasma and erythrocytes is probably due to the low lipophilicity of the drug. However, the latter characteristic did not seem to impede its diffusion across the placenta to any great degree.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6586489

Source DB:  PubMed          Journal:  Eur J Respir Dis Suppl        ISSN: 0106-4347


  10 in total

Review 1.  Pharmacokinetics of tocolytic agents.

Authors:  Vassilis Tsatsaris; Dominique Cabrol; Bruno Carbonne
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Investigation of distribution and elimination of terbutaline sulfate in the perfused rat liver preparation.

Authors:  Selma Sahin; Yasemin Karabey
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

3.  In utero exposure to β-2-adrenergic receptor agonist and attention-deficit/hyperactivity disorder in children.

Authors:  Hong Liang; Jianping Chen; Maohua Miao; Jakob Christensen; Søren Dalsgaard; Wei Yuan; Jiong Li
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-02-09       Impact factor: 4.785

Review 4.  A risk-benefit assessment of therapies for premature labour.

Authors:  K Higby; C R Suiter
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

Review 5.  Enantioselective disposition of albuterol in humans.

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

Review 6.  Placental transfer of drugs administered to the mother.

Authors:  G M Pacifici; R Nottoli
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of beta-agonists.

Authors:  D J Morgan
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

8.  Prenatal exposure to β2-adrenergic receptor agonists and risk of autism spectrum disorders.

Authors:  Lisa A Croen; Susan L Connors; Marilyn Matevia; Yinge Qian; Craig Newschaffer; Andrew W Zimmerman
Journal:  J Neurodev Disord       Date:  2011-08-27       Impact factor: 4.025

9.  Risk of childhood cerebral palsy following prenatal exposure to ß2-adrenergic receptor agonist: A nationwide cohort study.

Authors:  Lin Li; Ziliang Wang; Hong Liang; Fen Yang; Wei Yuan; Bizu Gelaye; Yongfu Yu; Maohua Miao; Mette Nørgaard; Jiong Li
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

Review 10.  Autism spectrum disorders: let's talk about glucose?

Authors:  Silvia Hoirisch-Clapauch; Antonio E Nardi
Journal:  Transl Psychiatry       Date:  2019-01-31       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.